Susanne Ragg MD, PhD
Associate Professor of Pediatrics
705 Riley Hospital Drive, ROC 4340
Indianapolis, IN 46202
Pediatric Hematology Oncology
Areas of Interest
Clinical interest: oncology and chelation therapy, clinical trials. Research interest: Proteomics in cancer (Wilms tumor, osteosarcoma, neuroblastoma), sickle cell disease, childhood obesity and inflammatory bowel syndrome as well as glaucoma; Biobank collection and storage of serum, plasma, urine, aqueous and vitreous fluid.
The focus of Dr Ragg's clinical research involves the study of serum proteins in many childhood disease including cancer, sickle cell disease, obesity and inflammatory bowel disease. Dr. Ragg has designed many studies to collect the serum of children with different diseases; she implemented the computational infrastructure required for large biobanking efforts as well as the analytical procedures required to compare the serum proteins in different diseases.
|1990||M.D. Ruprecht-Karls-Universität Heidelberg, Germany|
|1991||Ph.D. Institute for Genetics and Anthropology Ruprecht-Karls-Universität Heidelberg, Germany|
|1991-1992||Internship in Pathology; Ruprecht-Karls-Universität Heidelberg, Germany|
|1993-1996||Residency in Pediatrics, Childrens Hospital Los Angeles|
|1996-1999||Fellowship in Pediatric Oncology/Hematology, Riley Hospital for Children, Indiana University School of Medicine|
|2000-2002||National Library of Medicine Fellowship in Medical Informatics/Bioinformatics, Regenstrief Institute for Health Care|
|2007||M.S. Indiana University, School of Medicine|
Honors & Awards
- 1990 German Academic Exchange Service Scholarship to study medicine in the USA
- 1991 Magna Cum Laude for PhD thesis
- 1998 William Kennedy Research Award, National Childhood Cancer Foundation
- 1999 American Society of Hematology Scholar Award
- 2001 Travel Award, American Society of Hematology
Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
Research & Grants
For many pediatric diseases, such as sickle cell disease and cancer, research has concentrated on studying individual biomarkers separately. We hypothesized that combining the information of many proteins as well as several diseases would give us a more comprehensive picture on the changes of the serum proteome as it relates to different disease. We use an integrated approach that measures several hundred proteins by protein antibody array as well as by Liquid chromatography-tandem mass spectrometry. In collaboration with the Children Oncology Group we have analyzed the proteomic signature of children with osteosarcoma, Wilms tumor and neuroblastoma and are currently comparing the signature of children with cancer to other disease such as sickle cell disease, obesity and inflammatory bowel syndrome.
Clough T, Thaminy S, Ragg S, Aebersold R, Vitek O. Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs. BMC Bioinformatics 2012;13 Suppl 16:S6.
Zheng C, Zhang S, Ragg S, Raftery D, Vitek O; Identification and Quantification of Metabolites in 1H NMR Spectra by Bayesian Model Selection; Bioinformatics 2011;27:1637-44.
Clough T, Braun L, Fokin V, Ott I, Ragg S, Schadow G, Vitek O; Statistical design and analysis of label-free LC-MS proteomic experiments: A case study of coronary artery disease Methods in Molecular Biology 2011;238:293-319.
Clough T, Key M, Ott I, Ragg S, Schadow G, Vitek O. Protein quantification in label-free LC-MS experiments. J Proteome Res. 2009 Nov;8(11):5275-84.
Höner zu Siederdissen C, Ragg S, and Rahmann S. Discovering biomarkers for myocardial infarction from SELDI-TOF spectra. Advances in Data Analysis, Springer 2007, 569-576.
Liu X, Plasencia M, Ragg S, Valentine SJ and Clemmer DE. Development of High-Throughput Dispersive LC-Ion Mobility-TOFMS Techniques for Analyzing the Human Plasma Proteome. Briefings in Functional Genomics and Proteomics 2004; 3: 177-86.
Pollock KE, Hartwell JR, Braber A, Cooper RJ, Kreklau EL, Jansen M, Ragg S, Bailey BJ, Schmidt M, Von Kalle C, Erickson LC, Williams DA. Effective in vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Human Gene Therapy. 2003; 14: 1703-14.
Jansen M, Sorg U, Ragg S, Flasshove M, Seeber S, Williams DA, Moritz T. Hematoprotection and Enrichment of Transduced Cells in vivo after Gene Transfer of MGMT140k into Hematopoetic Stem Cells. Cancer Gene Ther 2002; 9:737-46
Schmidt M, Hoffmann G, Wissler M, Lemke N, MuBig A, Glimm H, Williams DA, Ragg S, Hesemann CU, von Kalle C. Detection and Direct Genomic Sequencing of Multiple Rare Unknown Flanking DNA in Highly Complex Samples. Human Gene Therapy 2001; 12:743-749.
Ragg S, Xu-Welliver M, Bailey J, D’Souza M, Cooper R, Pegg AE, Williams DA. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoetic stem cells. Cancer Research 2000; 60: 5187-5195.